This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ravandi, F. Articles by Estrov, Z. Search for Related Content PubMed PubMed Citation Articles by Ravandi, F. Articles by Estrov, Z. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Modulation of Cellular Signaling Pathways

Prospects for Targeted Therapy in Hematological Malignancies

Department of Hematology/Oncology, The University of Illinois at Chicago, Chicago, Illinois 60612 [F. R.], and Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [M. T., Z. E.]

The high remission rates observed in patients with chronic myelogenous leukemia who receive Imatinib mesylate (Gleevec) indicate that targeted therapy for hematological malignancies is achievable. At the same time, progress in cellular biology over the past decade has resulted in a better understanding of the process of malignant transformation, a better classification of subtypes of each disease on the basis of molecular markers, and a better characterization of the molecular targets for drug development. These advances have already spawned the development of such effective agents as monoclonal antibodies and specific enzyme inhibitors. This review attempts to provide a practical introduction to the complex and growing field of targeted therapy in hematological malignancies.

This article has been cited by other articles:

				K. Ghias, C. Ma, V. Gandhi, L. C. Platanias, N. L. Krett, and S. T. Rosen 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma Mol. Cancer Ther., April 1, 2005; 4(4): 569 - 577. [Abstract] [Full Text] [PDF]